Frontier Capital Management Co. LLC Sells 159,050 Shares of DexCom, Inc. (DXCM)
Frontier Capital Management Co. LLC cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 25.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 458,723 shares of the medical device company’s stock after selling 159,050 shares during the period. Frontier Capital Management Co. LLC owned approximately 0.53% of DexCom worth $33,556,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of DexCom during the first quarter valued at $136,000. IFP Advisors Inc boosted its stake in shares of DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of DexCom during the first quarter valued at $164,000. Mn Services Vermogensbeheer B.V. boosted its stake in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares during the last quarter. Finally, Independent Portfolio Consultants Inc. boosted its stake in shares of DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after buying an additional 9 shares during the last quarter.
Shares of DexCom, Inc. (NASDAQ:DXCM) opened at 73.20 on Monday. The firm has a 50-day moving average price of $70.65 and a 200 day moving average price of $74.91. DexCom, Inc. has a 12-month low of $57.68 and a 12-month high of $96.38. The company’s market capitalization is $6.34 billion.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. During the same quarter in the previous year, the firm posted ($0.24) EPS. The firm’s revenue was up 24.3% compared to the same quarter last year. On average, equities research analysts predict that DexCom, Inc. will post ($0.77) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Frontier Capital Management Co. LLC Sells 159,050 Shares of DexCom, Inc. (DXCM)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/21/frontier-capital-management-co-llc-sells-159050-shares-of-dexcom-inc-dxcm.html.
DXCM has been the topic of several recent research reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $90.00 price target on shares of DexCom in a research note on Wednesday, June 7th. B. Riley reaffirmed a “buy” rating and issued a $95.00 price target on shares of DexCom in a research note on Tuesday, May 2nd. Jefferies Group LLC reduced their price target on DexCom to $91.00 and set a “buy” rating on the stock in a research note on Tuesday, May 9th. Oppenheimer Holdings, Inc. set a $98.00 price target on DexCom and gave the stock a “buy” rating in a research note on Wednesday, May 3rd. Finally, BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. DexCom has an average rating of “Buy” and an average target price of $87.00.
In other DexCom news, EVP Andrew K. Balo sold 3,200 shares of DexCom stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $69.06, for a total transaction of $220,992.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of DexCom stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $78.19, for a total value of $113,375.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,726 shares of company stock valued at $2,376,466. 1.70% of the stock is currently owned by insiders.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.